EBITDA Margin % is calculated as EBITDA divided by its Revenue. Radiant Innovation's EBITDA for the
three
months ended in Dec. 2025 was NT$-15.6 Mil. Radiant Innovation's Revenue for the
three
months ended in Dec. 2025 was NT$93.9 Mil. Therefore, Radiant Innovation's EBITDA margin for the quarter that ended in Dec. 2025 was -16.59%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Radiant Innovation EBITDA Margin % Related Terms
Radiant Innovation EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Radiant Innovation's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:3373 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Radiant Innovation's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Radiant Innovation EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Radiant Innovation's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Radiant Innovation's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Radiant Innovation (ROCO:3373) has a EBITDA Margin % of -16.59% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Radiant Innovation and its competitors. According to the industry distribution chart, Radiant Innovation ranks #568 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 69.5%.
Is Radiant Innovation's EBITDA Margin % too high?
Radiant Innovation's current EBITDA Margin % is -16.59%. Based on the distribution chart, Radiant Innovation ranks #568 out of 817 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Radiant Innovation has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Radiant Innovation's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Radiant Innovation ranks #568 out of 817 companies for EBITDA Margin %. This places Radiant Innovation in the lower half of its industry. The industry median EBITDA Margin % is 7.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.44, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Radiant Innovation and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Radiant Innovation's current EBITDA Margin % is -16.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiant Innovation stock overvalued right now?
Based on GuruFocus' analysis, Radiant Innovation (ROCO:3373) is currently considered Fairly Valued. The stock's GF Value™ is NT$16.69, compared to a current price of NT$16.55 — trading 0.8% below its estimated fair value. The current EBITDA Margin % is -16.59%. Radiant Innovation's overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Radiant Innovation (ROCO:3373), the current EBITDA Margin % is -16.59% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Radiant Innovation (ROCO:3373) Overvalued in 2026?
Based on GuruFocus' analysis, Radiant Innovation stock appears to be undervalued.
The current stock price of NT$16.55 is trading 0.8% below its estimated GF Value™ of NT$16.69.
GuruFocus considers Radiant Innovation to be Fairly Valued.
Key valuation signals for ROCO:3373:
EBITDA Margin %: -16.59%
GF Value™: NT$16.69 vs. price of NT$16.55 (0.8% below fair value)
No single metric tells the full story. See the ROCO:3373 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Radiant Innovation Inc is engaged in the manufacture and distribution of medical instruments in Taiwan. It provides infrared ear thermometers, multi-function thermometers, infrared forehead thermometers as well as carbon dioxide detectors.
67GF Score
Get the complete analysis for ROCO:3373
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:3373 has been successfully added to your 
